candesartan cilexetil has been researched along with Left Ventricular Hypertrophy in 24 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| " In an 8-week, randomized, double-blind, placebo-controlled trial in patients with mild-to-moderate hypertension, the antihypertensive effects of candesartan cilexetil 16 mg were maintained after a missed dose, whereas systolic and diastolic blood pressure increased toward baseline levels after a missed dose of losartan 100 mg." | 9.09 | Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. ( Dell'Oro, R; Grassi, G; Mancia, G; Turri, C, 1999) |
| "Using cine magnetic resonance imaging (MRI) and echocardiography, we investigated the effects of candesartan cilexetil, a specific angiotensin II type 1 (AT1) receptor antagonist, on left ventricular (LV) mass and hemodynamics in patients with essential hypertension." | 9.08 | Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. ( Endoh, S; Inoue, S; Kinoshita, M; Maeda, K; Mitsunami, K; Okada, M; Sugihara, H; Takahashi, M, 1998) |
| " The new angiotensin II type I (AT1) receptor blocker candesartan cilexetil has been shown to be effective in reducing target-organ damage in animal models of hypertension, even at doses that do not produce significant reductions in blood pressure." | 8.80 | Preserving target-organ function with candesartan cilexetil in patients with hypertension. ( Zannad, F, 2000) |
| "To evaluate the preventive effect of regression of left ventricular hypertrophy (LVH) on sudden cardiac death (SCD), the incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion in Langendorff preparations was studied in the following five groups: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR treated with captopril (SHR-C), (3) SHR treated with the angiotensin II receptor antagonist TCV-116 (SHR-A), (4) SHR treated with hydralazine (SHR-H), and (5) Wistar-Kyoto (WKY) rats." | 7.69 | Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. ( Kanno, M; Kitabatake, A; Kohya, T; Nakaya, H; Saito, H; Tohse, N; Yokoshiki, H, 1995) |
| "Candesartan cilexetil is an effective antihypertensive agent with a tolerability profile similar to that of placebo." | 6.41 | Candesartan cilexetil: an update of its use in essential hypertension. ( Easthope, SE; Jarvis, B, 2002) |
| " In an 8-week, randomized, double-blind, placebo-controlled trial in patients with mild-to-moderate hypertension, the antihypertensive effects of candesartan cilexetil 16 mg were maintained after a missed dose, whereas systolic and diastolic blood pressure increased toward baseline levels after a missed dose of losartan 100 mg." | 5.09 | Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. ( Dell'Oro, R; Grassi, G; Mancia, G; Turri, C, 1999) |
| "Using cine magnetic resonance imaging (MRI) and echocardiography, we investigated the effects of candesartan cilexetil, a specific angiotensin II type 1 (AT1) receptor antagonist, on left ventricular (LV) mass and hemodynamics in patients with essential hypertension." | 5.08 | Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. ( Endoh, S; Inoue, S; Kinoshita, M; Maeda, K; Mitsunami, K; Okada, M; Sugihara, H; Takahashi, M, 1998) |
| " The new angiotensin II type I (AT1) receptor blocker candesartan cilexetil has been shown to be effective in reducing target-organ damage in animal models of hypertension, even at doses that do not produce significant reductions in blood pressure." | 4.80 | Preserving target-organ function with candesartan cilexetil in patients with hypertension. ( Zannad, F, 2000) |
| "To evaluate the preventive effect of regression of left ventricular hypertrophy (LVH) on sudden cardiac death (SCD), the incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion in Langendorff preparations was studied in the following five groups: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR treated with captopril (SHR-C), (3) SHR treated with the angiotensin II receptor antagonist TCV-116 (SHR-A), (4) SHR treated with hydralazine (SHR-H), and (5) Wistar-Kyoto (WKY) rats." | 3.69 | Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. ( Kanno, M; Kitabatake, A; Kohya, T; Nakaya, H; Saito, H; Tohse, N; Yokoshiki, H, 1995) |
| "Previously, we reported that an orally active angiotensin II (Ang II) receptor antagonist Losartan induces regression of left ventricular hypertrophy with reduction in the tissue Ang II contents in spontaneously hypertensive rats (SHR)." | 3.69 | TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats. ( Fukuchi, S; Katoh, K; Mizuno, K; Niimura, S, 1994) |
| "Candesartan cilexetil is an effective antihypertensive agent with a tolerability profile similar to that of placebo." | 2.41 | Candesartan cilexetil: an update of its use in essential hypertension. ( Easthope, SE; Jarvis, B, 2002) |
| "Candesartan cilexetil-treated banded rat hearts displayed shorter QT intervals and lower vulnerability to atrial and ventricular tachyarrhythmias than vehicle-treated banded hearts." | 1.72 | Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction. ( Chang, GJ; Chen, WJ; Ko, YS; Lai, YJ; Lee, YS; Yeh, YH, 2022) |
| " RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm." | 1.35 | A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. ( Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008) |
| " Combining candesartan-cilexetil with ramipril increased SBP reduction synergistically rather than additively, since the dose-response curve was shifted 6." | 1.32 | Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. ( Dominiak, P; Gieselberg, A; Jöhren, O; Raasch, W; Schwartz, S, 2004) |
| "Vascular hypertrophy is considered to be an adaptive response to increased arterial wall stress in hypertension." | 1.30 | Effect of angiotensin II receptor antagonism on vascular hypertrophy and aortic impedance in abdominal aortic-banded rat. ( Kobayashi, S; Kohno, M; Konishi, M; Matsuzaki, M; Obayashi, M; Ohkusa, T; Yamamoto, T; Yano, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (50.00) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 2 (8.33) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, GJ | 1 |
| Yeh, YH | 1 |
| Chen, WJ | 1 |
| Ko, YS | 1 |
| Lai, YJ | 1 |
| Lee, YS | 1 |
| Kishi, T | 1 |
| Hirooka, Y | 1 |
| Sunagawa, K | 1 |
| Wang, Z | 1 |
| Niu, Q | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Liu, K | 1 |
| Liu, Y | 1 |
| Liu, J | 1 |
| Jin, F | 1 |
| Li, X | 1 |
| Wei, Y | 1 |
| Major, TC | 1 |
| Olszewski, B | 1 |
| Rosebury, W | 1 |
| Okerberg, C | 1 |
| Carlson, T | 1 |
| Ostroski, R | 1 |
| Schroeder, R | 1 |
| Kowala, MC | 1 |
| Leadley, R | 1 |
| Isobe, N | 1 |
| Taniguchi, K | 1 |
| Oshima, S | 1 |
| Ono, Z | 1 |
| Adachi, H | 1 |
| Toyama, T | 1 |
| Naito, S | 1 |
| Hoshizaki, H | 1 |
| Kamiyama, H | 1 |
| Mukawa, H | 1 |
| Toki, Y | 1 |
| Miyazaki, Y | 1 |
| Matsui, H | 1 |
| Okumura, K | 1 |
| Ito, T | 1 |
| Sakata, Y | 1 |
| Yamamoto, K | 1 |
| Mano, T | 1 |
| Nishikawa, N | 1 |
| Yoshida, J | 1 |
| Nakayama, H | 1 |
| Otsu, K | 1 |
| Suzuki, K | 1 |
| Tada, M | 1 |
| Hori, M | 1 |
| Miwa, T | 1 |
| Masuyama, T | 1 |
| Saupe, KW | 1 |
| Sobol, SC | 1 |
| Koh, SG | 1 |
| Apstein, CS | 1 |
| Raasch, W | 1 |
| Jöhren, O | 1 |
| Schwartz, S | 1 |
| Gieselberg, A | 1 |
| Dominiak, P | 1 |
| Kohya, T | 1 |
| Yokoshiki, H | 1 |
| Tohse, N | 1 |
| Kanno, M | 1 |
| Nakaya, H | 1 |
| Saito, H | 2 |
| Kitabatake, A | 1 |
| Yamazaki, T | 2 |
| Shiojima, I | 2 |
| Komuro, I | 2 |
| Nagai, R | 1 |
| Yazaki, Y | 1 |
| Takeda, K | 1 |
| Fujita, H | 1 |
| Nakamura, K | 1 |
| Uchida, A | 1 |
| Tanaka, M | 1 |
| Itoh, H | 1 |
| Nakata, T | 1 |
| Sasaki, S | 1 |
| Nakagawa, M | 1 |
| Kojima, M | 1 |
| Zou, Z | 1 |
| Wang, Y | 1 |
| Mizuno, T | 1 |
| Ueki, K | 1 |
| Tobe, K | 1 |
| Kadowaki, T | 1 |
| Mizuno, K | 1 |
| Niimura, S | 1 |
| Katoh, K | 1 |
| Fukuchi, S | 1 |
| Kobayashi, R | 1 |
| Nagano, M | 1 |
| Nakamura, F | 1 |
| Higaki, J | 1 |
| Fujioka, Y | 1 |
| Ikegami, H | 1 |
| Mikami, H | 1 |
| Kawaguchi, N | 1 |
| Onishi, S | 1 |
| Ogihara, T | 1 |
| Sugimoto, K | 1 |
| Gotoh, E | 1 |
| Takasaki, I | 1 |
| Ebina, T | 1 |
| Iwamoto, T | 1 |
| Takizawa, T | 1 |
| Shionoiri, H | 1 |
| Ishii, M | 1 |
| Mitsunami, K | 1 |
| Inoue, S | 1 |
| Maeda, K | 1 |
| Endoh, S | 1 |
| Takahashi, M | 1 |
| Okada, M | 1 |
| Sugihara, H | 1 |
| Kinoshita, M | 1 |
| Hashida, H | 1 |
| Hamada, M | 1 |
| Hiwada, K | 1 |
| Obayashi, M | 1 |
| Yano, M | 1 |
| Kohno, M | 1 |
| Kobayashi, S | 1 |
| Yamamoto, T | 1 |
| Ohkusa, T | 1 |
| Konishi, M | 1 |
| Matsuzaki, M | 1 |
| Xie, Z | 1 |
| Gao, M | 1 |
| Togashi, H | 1 |
| Koyama, T | 1 |
| Mancia, G | 1 |
| Dell'Oro, R | 1 |
| Turri, C | 1 |
| Grassi, G | 1 |
| Zannad, F | 1 |
| Kobayashi, N | 1 |
| Nishikimi, T | 1 |
| Horinaka, S | 1 |
| Ishimitsu, T | 1 |
| Matsuoka, H | 1 |
| Easthope, SE | 1 |
| Jarvis, B | 1 |
3 reviews available for candesartan cilexetil and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Involvement of the renin-angiotensin system in the development of left ventricular hypertrophy and dysfunction.
Topics: Actins; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Calcium-Trans | 1994 |
Preserving target-organ function with candesartan cilexetil in patients with hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 2000 |
Candesartan cilexetil: an update of its use in essential hypertension.
Topics: Adsorption; Age Factors; Aged; Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2002 |
2 trials available for candesartan cilexetil and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 1998 |
Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive A | 1999 |
19 other studies available for candesartan cilexetil and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Atrial Remodeling; Benzimidazoles; Biphenyl Compounds; Calcium; Hyper | 2022 |
Telmisartan reduces mortality and left ventricular hypertrophy with sympathoinhibition in rats with hypertension and heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Hea | 2014 |
Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Gene E | 2016 |
A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Topics: Administration, Oral; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin | 2008 |
Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2002 |
Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Abdominal; Benzimidazoles | 2003 |
Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2+) regulatory proteins and extracellular matrix.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Effects of AT1 receptor block begun late in life on normal cardiac aging in rats.
Topics: Adenosine; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compoun | 2003 |
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2004 |
Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Body Weight; Capt | 1995 |
Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine; Benzimidazoles; Biphen | 1994 |
Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Hydra | 1994 |
TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihyperten | 1994 |
Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 1993 |
AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1996 |
Serial changes in sarcoplasmic reticulum gene expression in volume-overloaded cardiac hypertrophy in the rat: effect of an angiotensin II receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blott | 1999 |
Effect of angiotensin II receptor antagonism on vascular hypertrophy and aortic impedance in abdominal aortic-banded rat.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Abdominal; Benzimidazoles | 1999 |
Improvement in the capillarity of the left ventricular wall of stroke-prone spontaneously hypertensive rats following angiotensin II receptor blockade.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats.
Topics: Adrenomedullin; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Disea | 2001 |